Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

VBIV Jul 2022 2.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.03000.0000 (0.00%)
As of 02:20PM EDT. Market open.
Advertisement
Full screen
Previous Close0.0300
Open0.0300
Bid0.0000
Ask0.0500
Strike2.00
Expire Date2022-07-15
Day's Range0.0300 - 0.0300
Contract RangeN/A
Volume5
Open Interest380
  • Business Wire

    VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022

    CAMBRIDGE, Mass., June 28, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study (PROTECT) of the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, were presented in an oral presentation at The International Liver Congress™ 2022 (ILC), the Annual Meeting of the European

  • Business Wire

    VBI Vaccines Announces Results of Annual General Meeting

    CAMBRIDGE, Mass., June 22, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 22, 2022 (the "Meeting").

  • Business Wire

    VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

    CAMBRIDGE, Mass., June 22, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for VBI-1901, a bivalent gB/pp65 immunotherapeutic vaccine candidate for the treatment of glioblastoma (GBM). In June 2021, the FDA also granted Fast Track Designation for VBI-1901 for the treatment of recurrent GBM i

Advertisement
Advertisement